Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.
Domingo E, Kelly C, Hay J, Sansom O, Maka N, Oien K, Iveson T, Saunders M, Kerr R, Tomlinson I, Edwards J, Harkin A, Nowak M, Koelzer V, Easton A, Boukovinas I, Moustou E, Messaritakis I, Chondrozoumaki M, Karagianni M, Pagès F, Arnoux F, Lautard C, Lovera Y, Boquet I, Catteau A, Galon J; TransSCOT Consortium; Souglakos I, Church DN. Domingo E, et al. Among authors: church dn. J Clin Oncol. 2024 Mar 14:JCO2301648. doi: 10.1200/JCO.23.01648. Online ahead of print. J Clin Oncol. 2024. PMID: 38484206
Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.
Frei AL, McGuigan A, Sinha RRAK, Jabbar F, Gneo L, Tomasevic T, Harkin A, Iveson T, Saunders MP, Oien KA, Maka N, Pezzella F, Campo L, Browne M, Glaire M, Kildal W, Danielsen HE, Hay J, Edwards J, Sansom O, Kelly C, Tomlinson I, Kerr R, Kerr D, Domingo E; TransSCOT consortium; Church DN, Koelzer VH. Frei AL, et al. Among authors: church dn. Lancet Oncol. 2024 Feb;25(2):198-211. doi: 10.1016/S1470-2045(23)00560-0. Lancet Oncol. 2024. PMID: 38301689 Free article.
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.
Roseweir AK, Park JH, Hoorn ST, Powell AG, Aherne S, Roxburgh CS, McMillan DC, Horgan PG, Ryan E, Sheahan K, Vermeulen L, Paul J, Harkin A, Graham J, Sansom O, Church DN, Tomlinson I, Saunders M, Iveson TJ, Edwards J. Roseweir AK, et al. Among authors: church dn. J Pathol Clin Res. 2020 Oct;6(4):283-296. doi: 10.1002/cjp2.171. Epub 2020 May 13. J Pathol Clin Res. 2020. PMID: 32401426 Free PMC article.
The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.
Alexander PG, Roseweir AK, Pennel KAF, van Wyk HC, Powell AGMT, McMillan DC, Horgan PG, Kelly C, Hay J, Sansom O, Harkin A, Roxburgh CSD, Graham J, Church DN, Tomlinson I, Saunders M, Iveson TJ, Edwards J, Park JH. Alexander PG, et al. Among authors: church dn. Br J Cancer. 2021 Feb;124(4):786-796. doi: 10.1038/s41416-020-01168-x. Epub 2020 Nov 23. Br J Cancer. 2021. PMID: 33223535 Free PMC article.
Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study.
Wagner SJ, Reisenbüchler D, West NP, Niehues JM, Zhu J, Foersch S, Veldhuizen GP, Quirke P, Grabsch HI, van den Brandt PA, Hutchins GGA, Richman SD, Yuan T, Langer R, Jenniskens JCA, Offermans K, Mueller W, Gray R, Gruber SB, Greenson JK, Rennert G, Bonner JD, Schmolze D, Jonnagaddala J, Hawkins NJ, Ward RL, Morton D, Seymour M, Magill L, Nowak M, Hay J, Koelzer VH, Church DN; TransSCOT consortium; Matek C, Geppert C, Peng C, Zhi C, Ouyang X, James JA, Loughrey MB, Salto-Tellez M, Brenner H, Hoffmeister M, Truhn D, Schnabel JA, Boxberg M, Peng T, Kather JN. Wagner SJ, et al. Among authors: church dn. Cancer Cell. 2023 Sep 11;41(9):1650-1661.e4. doi: 10.1016/j.ccell.2023.08.002. Epub 2023 Aug 30. Cancer Cell. 2023. PMID: 37652006 Free PMC article.
Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets.
Frei AL, McGuigan A, Sinha RR, Glaire MA, Jabbar F, Gneo L, Tomasevic T, Harkin A, Iveson TJ, Saunders M, Oein K, Maka N, Pezella F, Campo L, Hay J, Edwards J, Sansom OJ, Kelly C, Tomlinson I, Kildal W, Kerr RS, Kerr DJ, Danielsen HE, Domingo E; TransSCOT Consortium; Church DN, Koelzer VH. Frei AL, et al. Among authors: church dn. J Pathol Clin Res. 2023 Nov;9(6):449-463. doi: 10.1002/cjp2.342. Epub 2023 Sep 11. J Pathol Clin Res. 2023. PMID: 37697694 Free PMC article.
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors.
Pennel KAF, Hatthakarnkul P, Wood CS, Lian GY, Al-Badran SSF, Quinn JA, Legrini A, Inthagard J, Alexander PG, van Wyk H, Kurniawan A, Hashmi U, Gillespie MA, Mills M, Ammar A, Hay J, Andersen D, Nixon C, Rebus S, Chang DK, Kelly C, Harkin A, Graham J, Church D, Tomlinson I, Saunders M, Iveson T, Lannagan TRM, Jackstadt R, Maka N, Horgan PG, Roxburgh CSD, Sansom OJ, McMillan DC, Steele CW, Jamieson NB, Park JH, Roseweir AK, Edwards J. Pennel KAF, et al. J Exp Clin Cancer Res. 2024 Mar 1;43(1):64. doi: 10.1186/s13046-024-02958-4. J Exp Clin Cancer Res. 2024. PMID: 38424636 Free PMC article.
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent D, Green E, McLeod H, Zanger UM, Schwab M, Braun M, Seymour M, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Jensen SA, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig P, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley R, Kerr D, Tomlinson I. Rosmarin D, et al. J Clin Oncol. 2014 Apr 1;32(10):1031-9. doi: 10.1200/JCO.2013.51.1857. Epub 2014 Mar 3. J Clin Oncol. 2014. PMID: 24590654 Free PMC article. Review.
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, Weaver A, Church D, Scudder C, Pearson S, Julier P, Pezzella F, Tomlinson I, Domingo E, Kerr DJ. Kerr RS, et al. Lancet Oncol. 2016 Nov;17(11):1543-1557. doi: 10.1016/S1470-2045(16)30172-3. Epub 2016 Sep 19. Lancet Oncol. 2016. PMID: 27660192 Clinical Trial.
75 results